Jasvinder A Singh1, John D Cleveland2. 1. J.A. Singh, MBBS, MPH, Medicine Service, VA Medical Center, Birmingham, and Department of Medicine at School of Medicine, and Division of Epidemiology at School of Public Health, University of Alabama at Birmingham; Jasvinder.md@gmail.com. 2. J.D. Cleveland, MS, Department of Medicine at School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Abstract
OBJECTIVE: To examine opioid use disorder (OUD)-related hospitalizations and associated healthcare utilization outcomes in people with 5 common musculoskeletal diseases (MSD). METHODS: We used the US National Inpatient Sample (NIS) data from 1998 to 2014 to examine the rates of OUD hospitalizations (per 100,000 NIS claims overall), time trends, and outcomes in 5 common rheumatic diseases: gout, rheumatoid arthritis (RA), fibromyalgia (FM), osteoarthritis (OA), and low back pain (LBP). RESULTS: OUD hospitalization rate per 100,000 total NIS claims in 1998-2000 vs 2015-2016 (and increase) were as follows: gout, 0.05 vs 1.88 (36-fold); OA, 0.68 vs 10.22 (14-fold); FM, 0.53 vs 6.98 (12-fold); RA, 0.30 vs 3.16 (9.5-fold); and LBP, 1.17 vs 7.64 (5.5-fold). The median hospital charges and hospital stays for OUD hospitalizations were as follows: gout, $18,363 and 2.5 days; RA, $17,398 and 2.4 days; FM, $15,772 and 2.1 days; OA, $16,795 and 2.4 days; and LBP, $13,722 and 2.0 days. In-hospital mortality rates ranged from 0.9% for LBP and FM to 1.7% for gout with OUD hospitalizations. Compared to those without each MSD, age-, sex-, race-, and income-adjusted total hospital charges (inflation-adjusted) for OUD hospitalizations with each rheumatic disease were as follows: gout, $697 higher; OA, $4759 lower; FM, $2082 lower; RA, $1258 lower; and LBP, $4944 lower. CONCLUSION: OUD hospitalizations increased in all 5 MSD studied, but the rate of increase differed. Awareness of these OUD hospitalization trends in 5 MSD among providers, policy makers, and patients is important. Development and implementation of interventions, policies, and practices to potentially reduce OUD-associated effects in people with rheumatic diseases is needed.
OBJECTIVE: To examine opioid use disorder (OUD)-related hospitalizations and associated healthcare utilization outcomes in people with 5 common musculoskeletal diseases (MSD). METHODS: We used the US National Inpatient Sample (NIS) data from 1998 to 2014 to examine the rates of OUD hospitalizations (per 100,000 NIS claims overall), time trends, and outcomes in 5 common rheumatic diseases: gout, rheumatoid arthritis (RA), fibromyalgia (FM), osteoarthritis (OA), and low back pain (LBP). RESULTS: OUD hospitalization rate per 100,000 total NIS claims in 1998-2000 vs 2015-2016 (and increase) were as follows: gout, 0.05 vs 1.88 (36-fold); OA, 0.68 vs 10.22 (14-fold); FM, 0.53 vs 6.98 (12-fold); RA, 0.30 vs 3.16 (9.5-fold); and LBP, 1.17 vs 7.64 (5.5-fold). The median hospital charges and hospital stays for OUD hospitalizations were as follows: gout, $18,363 and 2.5 days; RA, $17,398 and 2.4 days; FM, $15,772 and 2.1 days; OA, $16,795 and 2.4 days; and LBP, $13,722 and 2.0 days. In-hospital mortality rates ranged from 0.9% for LBP and FM to 1.7% for gout with OUD hospitalizations. Compared to those without each MSD, age-, sex-, race-, and income-adjusted total hospital charges (inflation-adjusted) for OUD hospitalizations with each rheumatic disease were as follows: gout, $697 higher; OA, $4759 lower; FM, $2082 lower; RA, $1258 lower; and LBP, $4944 lower. CONCLUSION: OUD hospitalizations increased in all 5 MSD studied, but the rate of increase differed. Awareness of these OUD hospitalization trends in 5 MSD among providers, policy makers, and patients is important. Development and implementation of interventions, policies, and practices to potentially reduce OUD-associated effects in people with rheumatic diseases is needed.
Authors: Michelle S Keller; Lyna Truong; Allison M Mays; Jack Needleman; Mary Sue V Heilemann; Teryl K Nuckols Journal: BMC Fam Pract Date: 2021-02-20 Impact factor: 2.497